AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

There’s no shortage of big promises about AI in healthcare. The U.S. government announced a $500 billion Stargate initiative ...

Using a recent survey on the adoption of AI/ML conducted by the Tufts CSDD as context, pharma leaders discussed how they are using these technologies to optimize trial execution.

Peter Ronco, CEO, Emmes, explains how public sector leaders are driving innovation in clinical development through automation, long-term data utilization, and experimental trial design—despite the ...

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in ...

IQVIA’s new AI orchestrator agents — powered by IQVIA Connected Intelligence and NVIDIA AI Foundry — speed clinical trials ...

Discover how digital innovation in clinical trial technology—eClinical platforms, remote data capture, and decentralized ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech ...

The landscape of clinical trials is rapidly transforming. As we move through 2025, smarter technologies and patient-centric ...

AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...

Dublin's Mater Misericordiae University Hospital (MMUH) has launched a new Centre for AI and Digital Health which will use ...

Supply chains for a new generation of therapies are complex, costly, and require meticulous management to ensure patient ...